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Summary 
 
Cardiogenesis in mammals requires exquisite control of gene expression and faulty regulation 
of transcriptional programs underpins congenital heart disease (CHD), the most common defect 
among live births. Similarly, many adult cardiac diseases involve transcriptional changes and 
sometimes have a developmental basis.  Long non-coding RNAs (lncRNAs) are a novel class of 
transcripts that regulate cellular processes by controlling gene expression; however, detailed 
insights into their biological and mechanistic functions are only beginning to emerge. Here, we 
discuss recent findings suggesting that lncRNAs are important factors in regulation of 
mammalian cardiogenesis and in the pathogenesis of CHD as well as adult cardiac disease. We 
also outline potential methodological and conceptual considerations for future studies of 
lncRNAs in the heart and other contexts. 
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Introduction 
The human genome project has opened the door for understanding development and disease at 
an unprecedented level. Once referred to as dark matter or “junk DNA”, it is now thought that up 
to 90% of the human genome is actively transcribed and produces many different types of 
transcripts including protein-coding and non-coding RNA (Carninci et al, 2005; Kapranov et al, 
2007; ENCODE Project Consortium et al, 2012). Non-coding RNAs have been broadly 
classified according to transcript length as small and long non-coding RNAs, where long non-
coding RNAs (lncRNAs) are considered to be greater than 200 nucleotides and can comprise 
up to thousands of nucleotides. The biological and mechanistic functions of different small non-
coding RNA species have been extensively reviewed (Matera et al, 2007; Carthew & 
Sontheimer, 2009; Malone & Hannon, 2009; Ghildiyal & Zamore, 2009; Castel & Martienssen, 
2013). Much less is known, however, about the functions of lncRNAs, an apparently 
heterogeneous class of RNA molecules with emerging biological functions. 
 
LncRNAs are pervasively transcribed throughout the genome and the resulting transcripts 
display remarkable similarities to classical mRNAs in that they are transcribed by RNA 
Polymerase II (RNAP2) and are generally, but not always, alternatively spliced, 5’-capped, and 
polyadenylated (Derrien et al, 2012). In contrast to protein-coding genes, lncRNAs have limited 
coding potential as indicated by the lack of protein domains or significant open reading frames 
(ORFs). Moreover, lncRNAs display random codon usage and no significant bias towards silent 
nucleotide substitutions underscoring their low protein-coding potential; and these transcripts 
are rarely translated despite their engagement with ribosomes in some cases (Cabili et al, 2011; 
Lin et al, 2011; Ulitsky et al, 2011; Bánfai et al, 2012). Based largely on these criteria, a large 
number of lncRNA have been identified across eukaryotes, thousands of them in mouse and 
human (Ulitsky et al, 2011; Derrien et al, 2012). Remarkably, lncRNAs appear to be rapidly 
evolving and generally display low levels of sequence conservation. About one-third of all 
human lncRNAs have arisen only within the primate lineage (Derrien et al, 2012), while only a 
small subgroup of lncRNAs appear to be maintained throughout a range of species with 
conservation being generally most evident in their promoter regions (Chodroff et al, 2010; 
Ulitsky et al, 2011). Together, these data suggest that regulation of lncRNA expression patterns 
is important for the function of this class of transcripts.    
 
Based on their genomic location, lncRNAs can be further grouped into different classes of 
transcripts (Ulitsky et al, 2011; Derrien et al, 2012) (Figure 1A). For example, long intergenic (or 
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intervening) non-coding RNAs (lincRNAs) are located between coding or non-coding genes, and 
do not overlap the exons of other genes. lncRNA loci can also reside within the introns of 
protein-coding genes. Natural antisense transcripts (NATs) are produced from the opposite 
strand of a coding (or non-coding gene) but their transcription start site is located downstream 
relative to that of the coding gene, and these transcripts often display at least partial overlap 
with the coding sequence of the corresponding mRNA. LncRNAs are highly versatile in that they 
can partially base-pair with other RNA templates to form duplexes or with DNA which can lead 
to the formation of triplex structures (Figure 1B). Moreover, these transcripts can interact with a 
diverse repertoire of proteins. Thus, lncRNAs are thought to possess tremendous regulatory 
potential. 
 
In general, lncRNAs can act in cis to regulate neighboring genes or in trans to modulate 
expression of their target genes by employing a wide range of molecular mechanisms. For 
example, a subclass of lncRNAs with apparent enhancer-like activity, termed ncRNA-activating 
(ncRNA-a), has recently been found to activate neighboring genes in cis using a mechanism 
involving DNA-looping between the lncRNA and its target gene (Orom et al, 2010; Lai et al, 
2013). Evidence also indicates that a subset of lncRNAs regulates gene expression by acting in 
trans as recruiters or decoys for chromatin modifiers and transcription factors to activate or 
silence genes (Rinn et al, 2007; Khalil et al, 2009; Tsai et al, 2010; Ng et al, 2012; Klattenhoff et 
al, 2013; Grote et al, 2013). Notably, despite the lack of sequence conservation among 
lncRNAs, interactions with RNA binding proteins including Polycomb and Trithorax group 
members have been widely conserved between mouse and human (Guttman & Rinn, 2012). 
Alternatively, some lncRNAs have been reported to function as microRNA sponges, titrating 
these small transcripts away from their respective mRNA target (Cesana et al, 2011; Wang et 
al, 2013). LncRNAs have also been reported to influence mRNA splicing, translation, or 
degradation by binding to mRNAs or protein components of RNP complexes (Tripathi et al, 
2010; Yoon et al, 2012; Gong & Maquat, 2011). Thus, lncRNAs have roles in transcriptional and 
post-transcriptional gene regulatory events. Consequently, the biological functions of lncRNAs 
as well as their mechanisms of action are expected to be diverse and will require a great deal of 
functional sub-classification in the future.  
 
While most predicted lncRNAs await functional characterization, there are clear examples 
demonstrating prominent roles for these transcripts in a variety of cellular processes including 
dosage compensation (e.g. X chromosome inactivation), imprinting, regulation of cell cycle, and 
	   5	  
apoptosis (Lee & Bartolomei, 2013; Rinn & Chang, 2012). Moreover, lncRNAs have been 
shown to play roles in somatic cell differentiation programs as well as maintenance of cell fate 
(Guttman et al, 2011; Hu et al, 2011; Kretz et al, 2012; 2013). Thus, lncRNAs may represent a 
new layer of regulation in differentiation and lineage commitment. Consistent with these broad 
roles, this class of transcripts has also been implicated as contributing factors to diseases with 
developmental components such as cancer and neurological disorders (Ponting et al, 2009; 
Wapinski & Chang, 2011; Mercer & Mattick, 2013; Batista & Chang, 2013; Ng et al, 2013). The 
emerging links between lncRNAs and disease as well as their tissue-specific expression 
patterns indicate that lncRNAs comprise a core transcriptional regulatory circuitry with master 
regulators and further suggest that they represent new molecules for targeted therapy.  
 
Mammalian heart development is a tightly regulated process requiring exquisite control of 
transcriptional programs. Consistent with this idea, disruption of transcriptional networks 
underpins congenital heart disease (CHD) and certain forms of adult cardiac disease (Bruneau, 
2008; Srivastava, 2006a). In fact, heart disease is the leading cause of morbidity and mortality 
worldwide (WHO 2011) with dramatic effects on the life quality of patients as well as on the 
health care system. Thus, dissecting the transcriptional regulatory principles that govern heart 
development and tissue homeostasis in the adult heart is of great interest to developmental and 
molecular biologists as well as clinicians. While it is known that the activities of DNA binding 
transcription factors, chromatin regulators, and signaling molecules converge to control tissue 
specific gene expression programs during heart development (Olson, 2006; Srivastava, 2006b; 
Chang & Bruneau, 2012; Bruneau, 2013), it is likely that non-coding transcripts also contribute 
to this highly orchestrated process. For example, members of the class of small non-coding 
RNAs such as miRNAs have critical roles in fine-tuning gene expression patterns during heart 
development (Cordes & Srivastava, 2009; Liu & Olson, 2010). Of particular interest is the recent 
discovery of lncRNAs that function in cardiac lineage commitment and heart development, 
revealing an additional layer of complexity (Klattenhoff et al, 2013; Grote et al, 2013). Although 
a general picture is emerging, we are only beginning to understand the implications of lncRNA 
regulation in heart development and cardiac-related disease. Here, we discuss the newly 
emerging roles of lncRNAs and cite specific examples in the context of heart development and 
cardiac disease as well as present considerations for the identification of additional lncRNA 
regulators of this process from a methodological and conceptual point of view.  
 
Heart development is regulated by tight control of gene expression patterns 
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Heart development requires the concurrent differentiation of multiple cell types that must 
organize into a complex structure. This process necessitates tight control of gene expression 
patterns in a temporal and spatial manner (Srivastava, 2006b). In most species, the primitive 
heart is established by concordant expression of a highly conserved core cardiac transcription 
factor network (Olson, 2006; McCulley & Black, 2012). However, more complex structures such 
as those that comprise the multi-chambered mammalian heart may require additional species-
specific regulatory factors. For example, the Drosophila heart is shaped as a relatively simple 
linear tube consisting of three sections that transport the hemolymph along the anterior-
posterior body axis: heart proper, posterior aorta, and anterior aorta, with the beating heart 
proper being separated from the aorta by a cardiovascular valve (Medioni et al, 2009; Seyres et 
al, 2012) (Figure 2A). Mammalian heart development begins with formation of an analogous 
structure in embryogenesis, yet the developing heart undergoes a series of complex 
movements, rotations and subsequent refinement, resulting in a four-chambered heart with 
distinct in- and outflow tracts, cardiac valves separating the different compartments, and a 
mature conduction system (Harvey, 2002; Srivastava, 2006b; Vincent & Buckingham, 2010) 
(Figure 2B).  
 
Despite the distinct structural differences between the simple Drosophila heart and the more 
complex mammalian heart, the core transcription factor network is highly conserved between 
both organisms (Reim & Frasch, 2010) (Figure 2C). In fact, Drosophila heart development has 
been used as a model to identify novel gene interactions leading to human heart disease (Qian 
et al, 2011; Qian & Bodmer, 2012). Mutations affecting cardiac transcription factors are often 
causative for congenital heart defects (Bruneau, 2008; McCulley & Black, 2012). For example, 
mutations in GATA4 or NKX2.5, members of the core cardiac transcription factor network, lead 
to atrial and ventricular septum defects and Tetralogy of Fallot. While the binding of sequence 
specific transcription factors to gene regulatory elements such as promoters and distal 
enhancers drive heart development, it has become increasingly clear that additional 
mechanisms contribute to fine-tuning the cardiac regulatory network. For example, microRNAs 
(e.g. miR-1, -126, -138, -143, -145) have roles in cardiogenic processes including angiogenesis, 
establishment of cardiac cell polarity, development of the cardiac conduction system, cardiac 
patterning, or smooth muscle cell differentiation, respectively, and in many cases these miRNAs 
regulate and interact with the core cardiac transcriptional network (Cordes & Srivastava, 2009; 
Liu & Olson, 2010). Notably, some miRNAs have been shown to play analogous roles in 
Drosophila heart development (Nguyen & Frasch, 2006). Despite the similarities between lower 
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eukaryotes such as Drosophila and more complex organisms, the mechanisms that give rise to 
the additional complexity of heart formation and function in mammals are not well understood. 
Given the recent identification of thousands of lncRNAs and their unique representation and 
tissue specific expression across organisms, these transcripts may signify a new class of 
regulatory molecules in cardiac development, and their functions may represent key distinctions 
that give rise to the more complex sub-structures of the mammalian heart. 
 
LncRNAs function to regulate developmental transitions in cardiac commitment 
LncRNAs have emerged as potent regulators of gene expression and may represent an 
important part of what distinguishes higher organisms from simpler eukaryotes. While unicellular 
organisms dedicate the majority of their genome to protein-coding sequence (~73 percent in S. 
cerevisiae), this fraction decreases significantly in multicellular organisms such as Drosophila 
(~18 percent), and coding sequences represent only a minor fraction of DNA in mammals (e.g. 
~2-3 percent in humans) (Taft et al, 2007) (Figure 2D). Thus, it has been hypothesized that the 
ratio of non-coding compared to protein-coding transcripts in the genome, rather than the overall 
number of protein-coding genes, underpins organismal complexity. While this idea remains to 
be tested, the total number of lncRNAs transcripts increases dramatically from Drosophila to 
human (Figure 2E). For example, while mice and humans have thousands of putative lncRNA 
genes (Ponjavic et al, 2007; Ulitsky et al, 2011; Derrien et al, 2012; Sigova et al, 2013), recent 
estimates suggest that there are 17 (Tupy et al, 2005) and possibly upwards of ~1,000 lncRNA 
transcripts in Drosophila (Young et al, 2012), ~170 loci in C. elegans that specify ~272 lincRNAs 
(Nam & Bartel, 2012), and ~600 loci that produce ~700 transcripts in zebrafish (Ulitsky et al, 
2011; Pauli et al, 2012).  There are several caveats to this analysis however, as numbers of 
putative lncRNAs or subclasses such as lincRNAs can vary widely among studies given that 
different criteria are used to identify these transcripts in each case. Furthermore, the 
transcriptomes of lower eukaryotes have not been as thoroughly analyzed compared to mouse 
and human. Nevertheless, lncRNAs across multi-cellular organisms often display expression 
patterns that are highly tissue-specific, suggesting that at least some of these transcripts have 
roles in developmental processes (Cabili et al, 2011; Derrien et al, 2012). For example, many 
lncRNAs are expressed dynamically at specific developmental stages during cardiomyocyte 
differentiation (Wamstad et al, 2012). Indeed, two recent studies identified lncRNAs in mouse 
with functions in commitment to the cardiac lineage and heart development (Klattenhoff et al, 
2013; Grote et al, 2013), opening the door to the possibility that lncRNAs represent new modes 
of developmental regulation.  
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Braveheart, a lncRNA required for the specification of a common cardiac progenitor 
The lncRNA Braveheart (Bvht, AK143260) was discovered in mouse based on its unique 
expression pattern. Bvht is expressed at early developmental stages in mouse embryonic stem 
cells (mESCs) and also abundantly in the adult heart relative to other differentiated tissues 
suggesting that this lncRNA may be important for specification of the cardiac lineage. 
Consistent with this idea, depletion of Bvht in mESCs impaired formation of cardiomyocytes in 
multiple in vitro differentiation assays (Klattenhoff et al, 2013). Heart development involves the 
specification of cardiac progenitor cells within the lateral plate mesoderm. MESP1, an essential 
transcription factor that is conserved in vertebrates and some non-vertebrate chordate species 
(Saga et al, 1996; 1999; 2000; Satou et al, 2004; Kriegmair et al, 2013), marks the earliest 
known cardiac population during development as well as tissues that contribute to head 
mesenchyme (Bondue et al, 2008; Lindsley et al, 2008; David et al, 2008). MESP1 progenitors 
have the capacity to specify all cell types of the heart, including cardiomyocytes, endothelial 
cells, and cardiac smooth muscle cells. Notably, using an in vitro cardiomyocyte differentiation 
system, the investigators found that Bvht is required for induction of MesP1 and its downstream 
targets including the core cardiac transcription factors Gata4, Gata6, Hand1, Hand2, Tbx2, and 
Nkx2.5, among others. In contrast, mesoderm markers such as Brachyury and Eomes were 
expressed normally at early stages of differentiation and remained expressed upon loss of Bvht. 
Notably, both BRACHYURY and EOMES are necessary for proper induction of MesP1 (Costello 
et al, 2011; David et al, 2011). Together, these data suggested that Bvht is necessary for the 
transition from nascent to cardiac mesoderm.  
 
LncRNAs can function in trans by interacting with chromatin modifiers to mediate changes in 
gene expression (Guttman & Rinn, 2012). Notably, Bvht was found to interact with SUZ12, a 
core component of the Polycomb repressive complex 2 (PRC2) and loss of the lncRNA resulted 
in a failure to activate the cardiac gene expression program. Many of the transcription factors in 
the core cardiac network are targets of PRC2 mediated repression in ESCs and differentiation 
toward specific lineages requires the selective loss of PRC2 at subsets of these genes (Boyer et 
al, 2006). Upon Bvht depletion, PRC2 and its associated repressive modification H3K27me3 
remained enriched at the promoters of critical genes in the cardiovascular network, including 
MesP1, Gata6, Hand1, Hand2, and Nkx2.5. Thus, Bvht may function as a molecular decoy to 
regulate expression of the core cardiac network (Figure 3A). However, whether Bvht regulates 
expression of the core cardiac network directly via its PRC2 binding activity or if it employs 
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additional molecular mechanisms to promote cardiac commitment remains an open question.  
 
While in vitro ESC-based cardiomyocyte differentiation recapitulates many of the stages of 
gastrulation and specification of the cardiac lineage (Kattman et al, 2007; 2011; Wamstad et al, 
2012), it will also be critical to determine the function of Bvht during development on an 
organismal level. A conserved Bvht transcript was not identified in rat or human suggesting that 
it is a rapidly evolving transcript (Klattenhoff et al, 2013). Although evidence of a transcript in rat 
and human is lacking, there is some DNA sequence conservation at syntenic sites among the 
three organisms making Bvht a particularly interesting example to study in terms of genomic 
evolution. 
 
Fendrr, a lncRNA necessary for heart and body wall development in mice. 
The lncRNA Fendrr (Foxf1 adjacent non-coding developmental regulatory RNA; 
ENSMUSG00000097336) was recently identified in mouse as a potential regulator of heart 
development by virtue of its specific expression in the lateral plate mesoderm (Grote et al, 
2013). The lateral plate mesoderm gives rise to the heart and structures of the ventral body wall. 
Loss of Fendrr resulted in embryonic lethality in mice (~E13.5) and null embryos displayed open 
ventral body wall defects and hypoplastic ventricles, resulting in impaired heart function. 
Expression of a subset of cardiac transcription factors, Nkx2.5 and Gata6, was increased in 
Fendrr loss of function hearts accompanied by corresponding changes in H3K4me3 levels at 
their promoters, whereas other members of the core cardiac network, such as Gata4 and Tbx5, 
showed no changes. The Fendrr gene is proximal to Foxf1a, a gene that codes for a 
transcription factor involved in mesoderm formation. Consistent with a partial cis regulatory role 
for Fendrr, Foxf1a was also ectopically expressed in null animals. Fendrr interacted with PRC2 
components as well as WDR5, a member of TrxG/MLL complex, to regulate mesoderm specific 
genes. These results suggested that Fendrr regulates the balance between repressive and 
activating marks at key genes during development (Figure 3B), although it is not clear if both 
complexes simultaneously interact with the non-coding transcript. The authors suggest that 
targeting these complexes to specific genomic sites is in part mediated through interactions 
between predicted unstructured regions of Fendrr and DNA; however, this idea needs to be 
further experimentally tested. Interestingly, a syntenic transcript exists in the human genome 
(ENSG00000268388) suggesting a conserved role for Fendrr in human heart development.  
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The interaction of Fendrr with multiple chromatin modifier complexes appears to be an emerging 
theme in lncRNA biology. For example, the lncRNA HOTAIR interacts with the PRC2 complex 
via its 5’ end and with the H3K4 demethylase LSD1 via its 3’ end, the Kcnq1ot1 lncRNA binds to 
both PRC2 and G9a (catalyzing the repressive H3K9 methylation mark), and the ANRIL lncRNA 
interacts with PRC1 and PRC2 (Mercer & Mattick, 2013). These observations are consistent 
with suggestions that lncRNAs act as dynamic modular scaffolds in a range of species (Guttman 
& Rinn, 2012; Spitale et al, 2011), potentially even adapting their binding capacities through 
conformation switches despite their lack of sequence conservation. In the case of Fendrr it will 
be important to test whether both the PRC2 as well as TrxG/MLL binding activities contribute 
directly to target gene regulation and how these functions are controlled molecularly. On a 
biological level, it will be necessary to dissect the developmental pathways regulated by Fendrr, 
since it seems to affect specific and distinct sub-populations within the lateral plate mesoderm.  	  
There are a hundreds, if not thousands, of additional putative lncRNAs that are expressed 
during cardiogenesis, and in many cases even in a cell type-specific manner (Wamstad et al, 
2012). While Bvht and Fendrr appear to function through epigenetic regulation of developmental 
gene expression programs, further detailed analyses of these individual candidates is expected 
to lead to the identification of additional lncRNAs with diverse functions in cardiovascular 
development. Dissecting how the expression of lncRNAs is regulated in a tissue-specific 
manner will be necessary in order to integrate these non-coding transcripts into the 
transcriptional regulatory circuitry that governs cardiogenesis.  Similarly to protein-coding genes, 
lncRNAs appear to be regulated by cell type specific transcription factors. For example, in 
mESCs, a large subset of expressed lncRNAs is bound at their promoters by the key 
pluripotency regulators OCT4, SOX2, and NANOG (Guttman et al, 2011). Thus, it will also be of 
considerable interest to identify the set of transcription factors that regulate cardiac-specific 
lncRNAs in order to integrate this new class of regulators into the transcriptional regulatory 
circuitry of heart development. 
 
Cardiac disease and lncRNAs 
Mutations in key core cardiac transcription factors are causative for congenital heart disease 
and some adult cardiac-related diseases such as those that affect the heart muscle as well as 
the electrical circuits required for proper conduction. Given that lncRNAs appear to contribute to 
the regulation of cardiac networks, these transcripts are also expected to contribute to cardiac-
related pathologies. Because many cardiac-related conditions are heritable, recent efforts to 
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identify potential new disease loci for cardiovascular diseases have relied in part on genome 
wide association studies (GWAS). The principle of GWAS is to analyze variations in nucleotide 
sequence, referred to as single nucleotide polymorphisms (SNPs), within a population of 
individuals that are afflicted with a particular condition as a means to identify new disease loci 
(Kathiresan & Srivastava, 2012). Notably, 93% of GWAS hits fall outside protein-coding regions 
and emerging evidence indicates that non-coding DNA, including distal regulatory elements as 
well as lncRNA genes that do not overlap known protein-coding genes, is enriched for disease 
SNPs (Maurano et al, 2012). In support of this idea, a number of lncRNAs have been implicated 
in adult cardiac disease by analysis of genetic variation among individuals with cardiac traits. 
Other examples of lncRNAs implicated in cardiac disease include natural antisense transcripts 
(NATs) that are transcribed in the opposite direction of critical heart development and structural 
genes suggesting that these NATs can impact the expression of key cardiac genes.    
 
MIAT, a lncRNA associated with myocardial infarction 
MIAT (myocardial infarction associated transcript) or Gomafu/RNCR2 was identified by GWAS 
as a risk factor associated with patients having suffered myocardial infarction (Ishii et al, 2006). 
Several variants were identified as significantly associated with higher susceptibility to 
myocardial infarction compared to controls. In fact, a particular SNP was associated with 
increased transcription of MIAT. MIAT accumulates in the nucleus in specific nuclear bodies and 
displays high expression levels in the central nervous system and lower levels in other tissues 
(Ishii et al, 2006; Sone et al, 2007; Tsuiji et al, 2011). It has also been implicated in retinal cell 
specification in the mouse (Rapicavoli et al, 2010) and may have a role in splicing regulation 
(Tsuiji et al, 2011), however MIAT’s molecular role in myocardial infarction remains unknown. In 
some cases of cardiac disease, such as primary cardiomyopathy, the heart is directly affected, 
while in other cases cardiac disease results indirectly from conditions such as diabetes and 
inflammation, which increase the risk for developing atherosclerosis and coronary artery 
disease and eventually myocardial infarction. Consequently, the identification and functional 
validation of lncRNAs with roles in complex traits will be an added challenge. 
 
SRA, a bi-functional transcript implicated in dilated cardiomyopathy 
The steroid receptor RNA activator 1 (SRA1) gene generates both steroid receptor RNA 
activator protein (SRAP) as well as several noncoding SRA transcripts, depending on 
alternative transcription start site usage and alternative splicing (Cooper et al, 2011; Colley & 
Leedman, 2011). SRA1 non-coding transcripts act as co-activators of nuclear receptor signaling 
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in a ligand-dependent manner and are involved in regulating skeletal muscle differentiation by 
co-regulation of the muscle development gene MyoD (Caretti et al, 2006). The identification of 
genome wide significant SNPs coupled with linkage disequilibrium mapping implicated three co-
segregating genes including HBEFG, IK, and SRA1 as determinants of human dilated 
cardiomyopathy (Friedrichs et al, 2009). Consistent with this finding, depletion of any one of 
these three genes in zebrafish led to contractile defects in the animals. While there is a clear 
function for the SRA1 protein in several cellular processes, the contributions of the alternatively 
spliced non-coding transcripts must be independently addressed, as a function for the putative 
lncRNA has not been established.  
 
Natural antisense transcripts in cardiac disease 
Natural antisense transcripts (NATs) are non-coding RNAs transcribed on the opposite strand of 
a given protein or non-coding gene and often partially overlap with its exon sequence 
distinguishing this class from lincRNAs (see Figure 1A). While antisense transcription is a widely 
employed mechanism for regulating gene expression in eukaryotes from plants, to fungi, to 
mammals (Derrien et al, 2012; Zhang et al, 2012), we are only beginning to understand the 
functions of these transcripts. NATs often, but not always, regulate the expression of their 
corresponding sense RNA and may employ different molecular mechanisms to do so. This 
mode of regulation is particularly important given that gene dosage is critical for proper heart 
development and function. In some cases, the act of transcription rather than the lncRNA itself 
may be necessary to exert the functional consequences. Here, we consider the following 
examples of NAT lncRNAs that have been implicated in aspects of cardiac disease.  
 
The INK4/ARF locus comprises three tumor suppressor genes; INK4A, ARF, and INK4B, that 
have important roles in cell cycle regulation.  The INK4 locus is subject to Polycomb-mediated 
regulation under normal conditions, however, how Polycomb complexes are recruited to this 
locus was not known. This question is of particular interest because expression of these genes 
is disrupted in many human cancers. ANRIL (antisense noncoding RNA in the INK4 locus, also 
P15 antisense RNA or CDKN2B antisense RNA) is expressed from the opposite strand and 
antisense to INK4B. Notably, ANRIL appears to interact with SUZ12, a core subunit of the 
PRC2 complex and with the CBX7 component of the PRC1 complex and mediates epigenetic 
silencing of INK4 in cis (Kotake et al, 2011; Yap et al, 2010) (Figure 3C). ANRIL is expressed in 
immune cells, smooth muscle cells, and endothelium. A risk haplotype is associated with the 
region encompassing ANRIL for coronary disease, stroke, type 2 diabetes, as well as some 
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cancers (Burd et al, 2010; Pasmant et al, 2011). In fact, some of the SNPs identified by GWAS 
appear to affect splicing of ANIRL transcripts (Burd et al, 2010). While it is not yet clear how 
regulation of INK4a/INK4b or its antisense transcript ANRIL contributes to risk of cardiovascular 
disease, isoforms containing exons proximal to the INK4/ARF locus correlated with disease risk. 
Thus, understanding how ANRIL is regulated under normal and disease conditions will be an 
important next step toward understanding its function in controlling the expression of critical 
genes in the INK4 locus. 
 
Congenital heart disease as well as certain types of adult cardiac diseases can result from 
defects in the structural components of the heart, which are important for contraction and 
conduction functions. Alpha- and beta cardiac myosin heavy chains (MYH6 and MYH7, 
respectively) are part of the contractile machinery of the cardiac sarcomere. Notably, the ratio of 
MYH6 to MYH7 expression may constitute a developmentally regulated switch that correlates 
with heart maturation and cardiac performance (Miyata et al, 2000; Pandya & Smithies, 2011). 
For example, in mouse MYH7 levels are higher in the fetal heart whereas the MYH6/MYH7 ratio 
is higher in adult cardiomyocytes. Interestingly, the proportion of these two genes is also 
regulated by certain pathophysiological stress conditions that lead to hypertrophy where the 
ratio is more similar to the fetal heart (Hang et al, 2010; Pandya et al, 2008). Moreover, 
mutations in MYH6 and MYH7 are both associated with hypertrophic cardiomyopathy 
(Granados-Riveron et al, 2010). The Myh6 and Myh7 genes are juxtaposed in the genome in a 
head to tail manner, and the switch in their levels is partly regulated by expression of Myh7 
antisense RNA in mouse (Haddad et al, 2003) (Figure 3D). The antisense lncRNA is transcribed 
across the Myh7 locus from the opposite strand and its expression negatively correlates with 
MYH7 protein abundance. One model is that antisense transcription may block elongation of 
Myh7 by RNA Polymerase II as has recently been described for the Airn lncRNA (Latos et al, 
2012).  Thus, the act of transcription may be important while the transcript itself has no function. 
Notably, a corresponding syntenic non-coding transcript appears to exist in the human genome 
(although the ratio of MYH6/MYH7 is opposite in human) suggesting that antisense transcription 
also has a conserved role in regulating this switch and that aberrant expression or mutation of 
the antisense transcript is also associated with hypertrophic conditions in human disease. Thus, 
it will be of interest to carefully dissect the role of MYH7 antisense transcription in heart 
development and cardiac hypertrophy in response to stress or injury.   
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The atrial myosin light chain gene (Alc1), which is important for sarcomere function, seems to 
be regulated by its antisense transcript at the translational level by forming RNA duplexes. 
Notably, Alc1-antisense is increased in hypertrophic ventricles in patients with Tetralogy of 
Fallot, a form of congenital heart disease, resulting in low ALC1 protein levels (Ritter et al, 
1999). However, a direct role for Alc1-antisense transcription in regulating ALC1 levels requires 
further experimental validation. Cardiac troponin I (cTNI) is also essential for normal sarcomere 
function in the adult cardiomyocyte and its expression also appears to be regulated at the 
translational level by formation of cTNI sense-antisense duplexes (Podlowski et al, 2002). While 
elevated cTNI levels are correlated with ischemia and risk of heart failure, it should be noted 
that the role of the antisense transcript in disease has not yet been evaluated.  In both of these 
cases, antisense transcripts may be important for regulating gene expression through formation 
of RNA duplexes that function as substrates for recruitment of factors that degrade the mRNA or 
by physically blocking translation of the message (Figure 3E). Notably, mRNA and lncRNA 
molecules in the cytoplasm can form imperfect base-pairs through regions of homology such as 
ALU sequences, a common repeat element found in the human genome. This type of 
interaction triggers messenger mediated decay through recruitment of the dsRNA binding 
protein STAU1 (Gong & Maquat, 2011). Alternatively, mRNA-lncRNA interactions can stabilize 
the expression of protein-coding transcripts.  For example, the lincRNA TINCR interacts with a 
range of mRNAs important for human epidermal differentiation through a 25 base pair motif call 
the TINCR box (Kretz et al, 2013). In this case, TINCR-STAU1 interactions mediate stabilization 
of the message rather than decay. Consistent with this idea, other key proteins required for 
mRNA decay (i.e. UPF1 and UPF2) do not appear to play a role. Thus, it is possible that in 
some cases antisense transcripts contain regions of homology by overlapping with exon 
sequences of the corresponding mRNA to mediate post-transcriptional regulation of a protein-
coding gene.  Given the potential mechanisms of action of antisense lncRNAs, manipulation of 
sense transcripts associated with cardiac disease may be particularly amenable to therapeutic 
intervention by small transcripts such as siRNAs or antisense oligos.  
 
While the discovery of lncRNAs in cardiac biology is only in its infancy, these examples provide 
a rationale for undertaking broad investigations to identify additional lncRNAs with roles in the 
cardiovascular system. One theme that is emerging is that the expression levels of lncRNAs 
must be tightly controlled. Similar to examples represented here, aberrant expression of several 
lncRNAs has been implicated in disease pathogenesis such as cancer progression. For 
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example, increased HOTAIR levels correlate with metastatic potential in a range of cancers 
including those of the breast, prostate, and pancreas (Wapinski & Chang, 2011).  To this end, 
mutations or aberrant expression of lncRNAs is expected to reveal new disease pathways and 
possible therapeutic targets. Clearly, the link between lncRNAs and cardiac disease 
susceptibility and pathogenesis will require intensive efforts. Even in the case of cardiac-
associated lncRNAs that display no or limited function, these transcripts could also represent a 
new class of biomarkers for diagnostics based on their specific expression patterns in normal 
and pathological conditions such as response to injury or stress.  
 
Discovering new lncRNAs with functions in cardiac biology 
Given the mounting evidence that lncRNAs play key roles in many cellular processes including 
cellular differentiation, it is intriguing that this class of transcripts has largely eluded identification 
in classical genetic screens. This result might be explained by the fact that genomes of model 
organisms generally used for genetic screens appear to contain fewer lncRNAs compared to 
mice and humans (see Figure 2E), and that these transcripts are poorly conserved across 
species. Moreover, until recently, lncRNAs have been poorly annotated so such hits in genetic 
screens would have been discarded in many cases. Furthermore, mammals display high levels 
of genetic redundancy, which often masks mutational phenotypes and may also apply in the 
case of lncRNAs. While lncRNAs are generally poorly conserved among species, functional 
redundancy may arise from transcripts that appear unrelated on a sequence level since similar 
secondary structures can be achieved by different combinations of nucleotides. Because of the 
lack of conservation, randomly occurring mutations may also be less likely to affect lncRNA 
function than mutations in protein-coding genes, making it more difficult to identify mutants in 
loss of function genetic screens. Also, given the significant structural differences in the heart 
between vertebrates and non-vertebrate species, there may be key limitations to using 
conventional genetic screens in lower eukaryotes for identifying heart-associated lncRNAs. 
Nevertheless, more recent targeted approaches using RNAi to specifically deplete lncRNAs 
have been successfully used to screen for specific phenotypes of a large number of these non-
coding transcripts (Guttman et al, 2011; Chakraborty et al, 2012). 
 
The overall low sequence conservation of lncRNAs between species suggests that lncRNAs are 
an extremely fast evolving family of regulatory molecules (Cabili et al, 2011; Ulitsky et al, 2011; 
Derrien et al, 2012). Relatively few lncRNAs have sequence homologues in other species; 
however, their promoter sequences are generally conserved significantly more than their exonic 
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sequences (Chodroff et al, 2010; Ulitsky et al, 2011), suggesting that at least in some cases the 
tissue-specific expression of a given conserved lncRNA is important. High-throughput 
sequencing efforts across different tissues, developmental stages, and pathological conditions 
are expected to reveal potential new regulators of heart development and disease. For example, 
lncRNAs that show the same stage and development specific expression patterns in a given 
species may regulate similar processes. Specifically, lncRNAs whose expression patterns 
cluster with other regulators of heart development (i.e. guilt by association) such as key 
transcription factors and signaling molecules may reveal classes of lncRNAs with functions in 
particular biological pathways. Furthermore, comparing transcriptional profiles of similar 
developmental time points among mammals may also reveal lncRNAs with conserved functions 
despite a lack of sequence conservation.  
 
Given that lncRNAs appear to be regulated by sets of transcription factors similarly to mRNA 
genes, analysis of transcriptional programs in loss of function studies may also contribute to the 
identification of lncRNAs with particular roles that are downstream of key transcription factor 
genes. Alternatively, lncRNAs whose expression changes dramatically in response to 
environmental or developmental cues might reveal new effector lncRNAs. For example, induced 
expression of MesP1, a master regulator of cardiac commitment, leads to the concomitant up-
regulation of several lncRNAs during cardiomyocyte differentiation in mouse including Fendrr 
(Klattenhoff, Scheuermann, and Boyer, unpublished), suggesting that Fendrr is a downstream 
effector of MESP1.  
 
Along these lines, it will be of interest to analyze those lncRNAs that show changes in 
expression under stress conditions or in diseased hearts in human patients. Comparisons of 
lncRNA expression patterns may reveal new biomarkers for cardiac disease since lncRNAs 
show considerable changes in expression in some human cancers and in neurological function 
and diseases (Tsai et al, 2011; Ng et al, 2013; Mattick, 2011). In some cases, functional 
analysis of candidate transcripts involved in cardiac disease identified through profiling of 
human tissues may be possible by reprogramming patient-specific cells to induced pluripotent 
stem cells (iPS) followed by in vitro differentiation into cardiac lineages. This method has been 
used to successfully to model complex neurological and metabolic diseases (Bellin et al, 2012). 
Together these studies, combined with the wealth of GWAS data available for cardiac-related 
diseases, will likely lead to the identification of additional lncRNAs that represent new loci for 
studying disease pathology as well as novel targets for therapeutic intervention.  
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Dissecting how lncRNAs exert their functions on a molecular level will require precise in vivo 
models as well as in vitro cell differentiation systems that will enable biochemical and 
biophysical studies. Given the low level of sequence conservation and protein-coding potential, 
it is possible that some lncRNA function may depend on specific secondary structures. In 
contrast, unstructured regions may be important for interaction with other nucleic acids and this 
function may be critical for targeting lncRNAs to specific genomic sites as has recently been 
suggested for Fendrr (Grote et al, 2013). To test this notion and to determine the function of 
individual RNA domains, experimental analyses of secondary structures within lncRNAs across 
different species by physical and chemical methods will be necessary. These studies will 
provide templates for mutational analyses and for studying the interactions between lncRNAs 
and proteins or other nucleic acids. It is also possible that more detailed functional studies will 
facilitate the design of small molecule drugs for therapeutic intervention.  
 
 
Conclusions 
While several thousands of putative lncRNAs have been identified in mammals, only relatively 
few have been studied in any detail. Thus, we anticipate that during the next few years the field 
will witness the discoveries of many more developmental, cellular, and molecular processes that 
are regulated by lncRNAs. The identification of lncRNAs in cardiac biology will open new doors 
to dissecting the complex gene regulatory mechanisms that drive organogenesis as well as 
tissue homeostasis, and for understanding how failure to properly regulate developmental gene 
expression programs can lead to cardiac-related diseases. Knowledge of the genetic basis of 
heart development and cardiac-related diseases is of substantial value to the medical field and 
can lead to better genetic tests for disease susceptibility and identification of candidate genes 
for therapeutic interventions. Given their emerging roles, we also expect that lncRNAs will 
feature prominently in devising new strategies for stem cell-based regenerative therapies. 
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Figure legends 
 
Figure 1. LncRNAs are a heterogeneous class of transcripts and function to regulate 
gene expression by diverse mechanisms. A. Representative classes of long noncoding 
RNAs based on genomic location.  LncRNAs can be located and transcribed within introns of 
protein-coding genes (left), as intervening genes known as long intergenic or intervening 
noncoding RNAs (lincRNAs) that do not overlap with the exons of other genes (middle), or they 
can be located on the opposite strand of a coding or noncoding gene and transcribed in the 
antisense direction (right). B. Global mechanisms of lncRNA function. LncRNAs can function as 
molecular scaffolds by interacting with proteins such as transcription factors or components of 
chromatin modifying complexes to affect positive or negative regulation of gene expression (left 
	   26	  
panel). Proposed mechanisms of action include targeting proteins to specific genomic sites such 
as promoter regions by complementary interactions with DNA. Alternatively, interactions with 
DNA may prevent the binding of specific factors to the DNA template (middle). LncRNAs can 
also base-pair with other RNA molecules such as mRNAs or may act as a sponge for miRNAs.. 
This scenario is thought to lead to post-transcriptional gene silencing (right panel).  
 
 
Figure 2. The developmental complexity of heart development varies among organisms 
despite conserved core cardiac TF network. A. Drosophila heart development begins during 
embryonic stage 11 by specification of two contralateral rows of cardiogenic mesoderm and 
formation of cardioblasts. Cardioblasts migrate towards the midline at stage 13-14 and form a 
simple linear closed tube with a central lumen by stage 16-17, subsequently differentiating into 
more mature cardiomyocytes. B. The first steps of mammalian heart development proceed in a 
very similar manner, yet the mature heart is considerably more complex with two atrial and two 
ventricular chambers, connecting the systemic and pulmonary circuits via four valves and in- 
and outgoing vessels. The earliest step of mammalian cardiogenesis involve the bilateral 
specification of cardiac progenitor cell populations from the first heart field (FHF) in the anterior 
lateral plate mesoderm, which condense into two lateral heart primordia (mouse E7.5, human 
day 15) to form the cardiac crescent. The secondary heart field (SHF) constitutes a separate 
cell population at the medial sides of the two processes of the cardiac crescent. The two 
processes of the cardiac crescent fuse to form a beating primitive linear heart tube (mouse 
E8.5, human day 21), which then undergoes rightward looping, resulting in formation of the 
early chambers (mouse E9, human day 28). During later stages, the mature shape of the heart 
is generated by differentiation of cardiac cell populations and extensive remodeling of the heart, 
resulting in four-chambered heart with distinct in- and outflow tracts, cardiac valves separating 
the different compartments, and a mature conduction system. C. The core transcription factor 
network necessary for specification of the cardiovascular lineages are conserved between 
Drosophila and mammals. D. The percentage of noncoding to protein-coding sequence 
increases with developmental complexity. Whereas S. cerevisiae dedicates most of its genome 
to protein-coding genes, only a small fraction of the genome codes for proteins in human. E. 
The total number of putative lncRNA transcripts is predicted to be significantly higher in mouse 
(~3,000 lincRNA transcripts as determined by Ponjavic et al, 2007; Sigova et al, 2013) and 
Human (~15,000 as defined by Derrien et al, 2012) as compared to lower eukaryotes such as 
Drosophila (17 based on stringent criteria in Tupy et al., 2005 to greater than 1,000 based on 
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low stringency estimates from Young et al, 2012), C. elegans (262 from Nam & Bartel, 2012), 
and zebrafish (~700 transcripts predicted from Ultisky et al, 2011 and Pauli et al, 2012). The 
number of lncRNAs varies among studies as different criteria were used to define lncRNA 
transcripts. 
 
 
Figure 3. Mechanisms of lncRNA function in heart development and cardiac disease.  
A. Braveheart is necessary for commitment to the cardiac lineage in mouse.  Bvht appears to 
function in trans through interaction with the epigenetic silencing complex PRC2 and may act as 
a decoy to antagonize its recruitment to key developmental genes during cardiomyocyte 
differentiation. Alternatively, Bvht may recruit PRC2 to gene(s) that repress the cardiac program. 
In either case, loss of Bvht leads to a failure to activate the core cardiac gene network that 
includes many TFs implicated in heart development and disease. B. Fendrr is expressed in the 
lateral plate mesoderm in mouse from which precursors for the heart and body wall are derived.  
Fendrr is proposed to function partly in cis to regulate its neighboring gene Foxf1a. Fendrr also 
functions in trans to regulate the expression of additional genes important for heart 
development. Fendrr interacted with PRC2 components as well as WDR5, a member of 
TrxG/MLL complex suggesting that Fendrr regulates the balance between repressive and 
activating marks at key genes during development. Thus, Bvht and Fendrr may represent 
examples of lncRNAs that regulate gene expression through epigenetic mechanisms. C-E. 
LncRNAs can also function as natural antisense transcripts (NATs) to affect gene expression at 
the transcriptional and post-transcriptional level. ANRIL was identified as a risk factor for 
coronary disease by GWAS. ANRIL is expressed in the opposite direction to INK4B/P15 in the 
INK4 locus.  The antisense transcript appears to recruit PRC1 and PRC2 to mediate repression 
of the INK4a/INK4b tumor suppressor locus through an epigenetic silencing mechanism (C). 
The ratio of two important sarcomere components MYH6 and MYH7 vary during development 
and in stress-induced pathological conditions. Myh6 and Myh7 genes are juxtaposed in the 
mouse genome in a head to tail fashion. An antisense lncRNA (Myh7-as) is transcribed across 
the Myh7 locus and negatively correlates with MYH7 abundance. Thus, Myh7-as transcription 
may regulate the ratio of Myh6 and Myh7 (D). Some antisense transcripts are predicted to form 
RNA duplexes with their mRNA counterpart leading to post-transcriptional regulation of the 
target message. For example, antisense transcripts to Alc1 and cNTI, two genes that code for 
important sarcomere components in cardiac muscle, form RNA duplexes with the respective 
protein-coding transcript. Alc1-antisense is increased in hypertrophic ventricles in patients with 
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Tetralogy of Fallot, whereas elevated cTNI levels are correlated with ischemia and risk of heart 
failure. In both of these cases, antisense transcripts may be important for regulating gene 
expression through formation of RNA duplexes that are substrates for recruitment of factors that 
degrade the mRNA or that physically block translation of the message. RNA-RNA interactions 
can also stabilize the mRNA in some cases (E). 	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